Cargando…
KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma
We reported that histone H3 lysine (K) 4 methyltransferase, KMT2D, serves as a potent tumor-suppressor in melanoma, which was identified via in vivo epigenome-focused RNA interference (RNAi) screen. KMT2D-deficient tumors show substantial reprogramming of key metabolic pathways including glycolysis...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632269/ https://www.ncbi.nlm.nih.gov/pubmed/34859145 http://dx.doi.org/10.1080/23723556.2021.1984827 |